Chemotherapy with or without talniflumate for breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether adding a medication called talniflumate to standard chemotherapy before breast cancer surgery helps treat the cancer better. It may help shrink tumors before surgery and improve your long-term outlook.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman between 18 and 75 years old.
- Your breast cancer must be confirmed by a biopsy (pathology test).
- You must not have received any anti-cancer treatment before starting this trial.
- Your liver and kidney function tests must be within acceptable limits (checked after surgery).
- Your blood counts must be healthy enough (hemoglobin, platelets, and white blood cells).
- You are expected to live at least 6 more months, and you must be able to take oral medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy before surgery to shrink breast tumors, which may make surgery easier or allow breast-conserving options. It is for adults with invasive breast cancer that has not spread to distant organs.
This trial tests a new drug (SHR-A1811) alone or with letrozole given before surgery to shrink early-stage breast cancer that is hormone receptor-positive and HER2-low. It may help make surgery more effective.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
This trial tests a new combination of immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy given before surgery for a certain type of breast cancer. The goal is to see if this approach can shrink tumors more effectively and improve outcomes.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.